After a recent presentation to investors at Stifel Jaws and Paws Conference last week, Zoetis faces investors yet again today.
NEW YORK – June 2, 2026 — Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, is participating today in a fireside chat at the prestigious William Blair 46th Annual Growth Stock Conference at 1:20 p.m. CT, marking the company’s second major investor conference appearance in just six days.
Event Details
Interested investors and industry observers can access the live audio webcast through Zoetis’ investor relations portal, with a replay made available following the presentation.
Back-to-Back Investor Engagements
Stock markets are brutal and when the going gets tough – you meet investors more often to present your side of story. This appearance follows Zoetis’ participation in the Stifel Jaws & Paws conference on May 28, marking the company’s second high-profile investor conference in just six days. While the transcript from the Stifel event has not yet been published, the market is closely watching whether Chief Financial Officer Wetteny Joseph will provide new insights during today’s William Blair presentation.
Key Questions Investors Are Watching
Markets are anticipating answers to several critical questions that could influence Zoetis’ stock trajectory and investor sentiment:
1. US Librela Trajectory Beyond Current Validation
The primary focus centers on whether CFO Wetteny Joseph will offer fresh color on the US Librela trajectory beyond the $210–215M range that was validated at the Stifel conference. Librela, Zoetis’ groundbreaking osteoarthritis pain treatment for dogs, has been a key growth driver, and investors are eager for updated market penetration and revenue projections
2. Cytopoint Plus Launch Timeline
Investors are seeking clarity on the Cytopoint Plus launch timeline. Cytopoint Plus represents an expanded formulation of Zoetis’ popular canine allergy treatment Cytopoint, and its market introduction could significantly impact the company’s dermatology portfolio revenues
3. Neogen GeneSeek Integration Progress
The market is also watching for commentary on the Neogen GeneSeek integration progress. The acquisition of GeneSeek, a leader in genetic testing solutions for livestock, represents a strategic expansion into precision agriculture and animal genomics, and investors are keen to understand integration milestones and synergy realization
Pipeline Innovations Under the Spotlight
Zoetis materials highlight ongoing R&D work across multiple therapeutic areas that will likely come under scrutiny from William Blair’s growth investor audience:
Therapeutic Pipeline Areas:
Approved Long-Acting Osteoarthritis Products:
Zoetis is also highlighting two recently approved long-acting osteoarthritis pain products that represent significant pipeline optionality:
Earnings Pressure and Pipeline Optionality
Today’s presentation comes during a period of earnings pressure for Zoetis, making the William Blair audience particularly interested in probing for pipeline optionality beyond the current challenges. The company faces competitive pressures in key markets while navigating regulatory approvals and market adoption of new products.
Growth investors at William Blair will likely focus on:
-
Revenue diversification beyond current core products
-
Long-term growth trajectory amid near-term headwinds
-
R&D investment efficiency and pipeline advancement timelines
-
Regulatory approval pathways for novel therapeutics
-
Market expansion opportunities in emerging economies
